Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil

ZD1839 (‘Iressa’), an orally active, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is currently being investigated in clinical trials as a treatment for cancer. ‘Iressa’ is a trademark of the AstraZeneca group of companies. We have previously demonstrated a synergistic interaction between ZD1839 and cisplatin/5-fluorouracil (5FU) in CAL33, a human head and neck cancer cell line that markedly expresses EGFR. This study examined the effects of this drug combination on the cell cycle, cell cycle regulators, apoptosis-related factors, EGFR-related signalling and DNA repair in CAL33 cells. The cells were incubated with ZD1839 alone for 48 h, then cisplatin and 5FU were added. Exposure to the drug combination continued for a further 48 h. ZD1839 alone induced accumulation of cells in the G0/G1 phase of the cell cycle at 24 h accompanied by a concomitant increase in p21, p27 and Bax, a significant decrease in Bcl2 and a decrease in Akt phosphorylation. A decrease in DNA-PK was observed at 48 h. ZD1839 alone had no effect on caspase-3 activity, but addition of ZD1839 to cisplatin-5FU led to a significant increase in caspase-3 activity at 96 h. Thus, ZD1839 affects key cellular pathways controlling cell proliferation, apoptosis and DNA repair. These data provide a rationale to support clinical trials combining ZD1839 and cisplatin–5FU and other protocols that combine EGFR-targeting agents with chemotherapy or radiotherapy.

British Journal of Cancer (2003) 89, 585–592. doi:10.1038/sj.bjc.6601131 www.bjcancer.com © 2003 Cancer Research UK

Keywords: ZD1839; ‘Iressa’, fluorouracil, cisplatin, head and neck cancer, molecular mechanisms

ZD1839, confirming the radiosensitisation conferred by an EGFR-targeting agent. We also reported a synergistic interaction between ZD1839 and the cisplatin–5FU combination (Magné et al, 2002a). This synergistic cytotoxicity observed in vitro in the head and neck human cancer cell line CAL33 was strictly dependent on the order of combination, with optimum effects observed when ZD1839 was applied before and during cisplatin–5FU treatment. The present study was undertaken to elucidate the cellular mechanisms underlying the synergistic cytotoxicity of the ZD1839 plus cisplatin–5FU combination.

Targeting EGFR signalling with specific drugs affects cellular pathways involved in cell cycle regulation, apoptosis and DNA repair (Ciardiello et al, 2000; Huang and Harari, 2000; Sirotnak et al, 2000; Baselga, 2001; Yarden, 2001). The following parameters were thus investigated in the CAL33 cell line exposed to ZD1839 and cisplatin–5FU: cell proliferation markers (cell cycle, p42/p44, p-AKT, p21, p27), apoptosis factors (p53, Bax/Bcl2, CD95, caspase 3) and DNA-repair mechanisms (DNA-dependent protein kinase (DNA-PK), ATM). Changes in glutathione π transferase (GSTπ) expression were also investigated, as this is a key factor affecting the chemosensitivity to cisplatin (Cabelguenne et al, 2001).

MATERIALS AND METHODS

Chemicals

ZD1839 was kindly provided by AstraZeneca L, Rveic-Malmaison, France. Cisplatin and 5FU were provided by the pharmacy of the
Centre Antoine Lacassagne (Nice, France). A 50 mM working solution in dimethylsulfoxide (DMSO) was prepared before use. Dulbecco’s modification of Eagle’s medium (DMEM) and glucose were purchased from Whittaker (Verviers, Belgium). Fetal bovine serum (FBS) was obtained from Dutscher (Brumath, France). Penicillin and streptomycin were from Meyrieux (Lyon, France). Bovine serum albumin (BSA) and DMSO were purchased from Sigma (St Quentin Fallavier, France). Penicillin and streptomycin were purchased from Whittaker (Verviers, Belgium). Fetal bovine serum (FBS) was obtained from Dutscher (Brumath, France). Penicillin and streptomycin were from Meyrieux (Lyon, France). Bovine serum albumin (BSA) and DMSO were purchased from Sigma (St Quentin Fallavier, France).

Drug administration schedule

The human head and neck cancer cell line CAL33 was used in the present study as in our previous work (Magne et al, 2002a). CAL33 cells carry a p53 mutation (codon 175; CGC→CAC) and exhibit high EGFR expression (34 000 fmol mg⁻¹ protein). CAL33 has no intrinsic mitogen-activated protein (MAP) kinase activity or k-ras mutation (Magne et al, 2002b).

Cells were routinely cultured in DMEM supplemented with 10% FBS, 2 mM glutamine, 50 000 U l⁻¹ penicillin and 80 μM streptomycin, in a humidified incubator (Sanyo, Japan) at 37°C with an atmosphere containing 8% CO₂.

Cells were seeded in 175 cm² tissue culture flasks at 1.86 × 10⁶ cells to obtain exponential growth for the duration of the experiments. These conditions are comparable to 3000 cells per well in 96-well microtitration plates, as used in the previously published study (Magne et al, 2002a).

We investigated two different experimental schedules (Figure 1; see below), and cellular parameters were analysed at 0, 24, 48, 72 and 96 h after T₀, the onset of drug application.

Single-drug exposure Cells were exposed, 48 h after cell seeding, to ZD1839 alone at 6 μM (IC₅₀) for 96 h (condition ZD1839); 48 h after seeding, cells were exposed to medium alone for 48 h, followed by cisplatin and 5FU together at their IC₅₀’s (0.15 and 3.3 μM, respectively) for a further 48 h (condition cisplatin–5FU; Figure 1). Cisplatin–5FU was considered to be a single drug for the purpose of this study.

Drug combination CAL33 cells were exposed, 48 h after seeding, to ZD1839 at 6 μM alone for 48 h. Cisplatin and 5FU (0.15 and 3.3 μM, respectively) were then added, and exposure to the three-drug combination continued for a further 48 h (condition ZD1839–cisplatin–5FU) (Figure 1). The cytotoxic effects resulting from this drug combination were analysed as described previously (Magne et al, 2002a). A mean combination index (according to Chou and Talalay, 1984) of 0.4 was found, which confirmed the existence of the previously reported synergistic cytotoxic activity (Magne et al, 2002a).

All investigations were performed in triplicate during separate experiments for all cellular parameters.

Cell cycle analysis

Cell cycles were analysed by FACS according to the Vindelov model. A total of 2 × 10⁶ CAL33 cells in exponential growth were treated with various concentrations of ZD1839 for 24 h and then washed three times with citrate buffer. The cell pellet was incubated with trypsin-containing citrate buffer (250 μl) for 10 min at room temperature and then incubated with 200 μl of citrate buffer containing a trypsin inhibitor and RNase (10 min) before adding propidium iodide (PI; 200 μl at 125 μg ml⁻¹). Samples were analysed on a Becton Dickinson FACScan flow cytometer using Modfit software, which was also used to determine the percentage of cells in the different phases of the cell cycle. Propidium iodide was excited at 488 nm, and fluorescence was analysed at 620 nm (FL-3).

Western blot analyses

The following parameters were analysed by Western blotting: p21, p27, Bax, Bcl2, p-AKT, p42–p44, DNA-PK and ATM.

Western blots were performed by harvesting total cellular lysates (4 × 10⁶ cells) in 50 μl of lysis buffer Laemmli 1 × (Laemmli 4 ×: 1.6 ml Tris-HCl, 1 mM, pH 7.5; 400 mg sodium dodecyl sulfate (SDS); 2 ml glycerol; 145 mM β-mercaptoethanol; 12% bromophenol), and were heated for 15 min at 95°C. The protein content of cytosolic preparations was determined by the method of Bradford using the Bio-Rad reagent with BSA as a standard. Equal amounts of protein (50 μg per lane) were separated by 12.5% SD–10% polyacrylamide gel electrophoresis (PAGE) and transferred onto a nitrocellulose membrane. Prestained molecular weight markers were included in each gel. Membranes were blocked for 30 min in TBS (10 mM Tris-HCl, pH 7.5; 150 mM NaCl) with 0.5% Tween-20 and 5% BSA. After blocking, membranes were incubated for approximately 12 h with the appropriate specific anti-human monoclonal antibody (dilution of 1:5000) in TBS Tween and 1% BSA: p21 (mouse anti-human monoclonal anti-p21 antibody, Santa Cruz Biotechnology, Tebu Bio Le Perray en Yveline, France), p27 (mouse anti-human monoclonal anti-p27 antibody, Santa Cruz Biotechnology), Bax (mouse anti-human monoclonal anti-Bax antibody, Santa Cruz Biotechnology), Bcl2 (mouse anti-human monoclonal anti-Bcl2 antibody, Santa Cruz Biotechnology), phosphorlated form of AKT (p-AKT, goat anti-human polyclonal anti-p-AKT antibody, Santa Cruz Biotechnology), p42–p44 (mouse anti-human monoclonal anti–MAP kinase activated antibody, diphosphorylated ERK-1&2, anti-DPERK, clone MAP kinase-YT, Sigma, St Quentin Fallavier, France), DNA-PK (goat anti-human polyclonal anti-DNA-PK antibody, Santa Cruz Biotechnology) and ATM (mouse anti-human monoclonal anti-ATM antibody, Santa Cruz Biotechnology). After washing the membranes three times with TBS Tween (5 min each), they were incubated with peroxidase-conjugated secondary antibodies purchased from Dako (dilution of 1:1000; Glosstrup, Denmark). A chemoluminescence reaction was performed and the membranes were exposed to ECL hyperfilm according to the manufacturer’s instructions (Amersham Pharmacia Biotech, Little Chalfont, UK). Quantitative analysis of activities was performed by imaging the autoradiograms and quantitating relative band densities using scan imaging software (Image Master, Pharmacia, Amersham Bioscience, Orsay, France).
p53 protein assay

p53 protein content (wild type and mutated forms) was analysed in cytosol (200 μl) using a monoclonal two-site single incubation immunoluminometric assay (LIA-mat, Sangtec, Sweden). A total of 10^6 cells were homogenised in lysis buffer (500 μl, 50 mM Tris-HCl pH 6.8, 1% Triton X-100, 2 mM phenylmethylsulfonyl fluoride (PMSF) and 0.02% mercaptoethanol); the samples were then centrifuged at 105 000 g for 30 min at 4°C before 200 μl aliquots were taken. The assay is based on the use of two monoclonal antibodies against different denaturing-resistant epitopes of the N-terminal part of the p53 protein. Polystyrene tubes were coated with PAb 1801 monoclonal anti-p53 antibody and the tracer consisted of isoluminol-conjugated D01 monoclonal antibody. The sensitivity limit was 0.002 ng·mg⁻¹ protein. The coefficient of variance for inter-assay reproducibility (pooled cytosol, n = 10) was 7.66%.

Detection of the CD95 (APO1-fas) receptor

In total, 10^6 cells were trypsinised, washed and exposed to 4 ng·μl⁻¹ of CH11 anti-Fas MAb for 45 min at 4°C. After two washing steps, cells were resuspended in DMEM containing 1:200 (v/v) goat anti-mouse IgM (Immunotech, Marseille, France) and incubated for an additional 30 min at 4°C. Cells were then washed twice, and cell surface expression of CD95 was assessed by FACScan. Analysis was carried out on a flow cytometer (FACScan, Becton Dickinson) for an additional 30 min at 4°C followed by 5 min at 94°C. The oligonucleotides used for GSTp amplification were GSTp sense strand: TAC ACC GTG TGC TAT TTC CC (nucleotides 27–46) and GSTp antisense strand: CTG TTT CCC GCC ATT GAT (nucleotides 627–647), which yield a 620 bp product. Those used for amplification of the reference gene (GAPDH) were GAPDH sense strand: GGA AGG TGA AGG TCG GAG TC (nucleotides 38–57) and GAPDH antisense strand: CAC AAG CTT CCC GTT GCC ATT GAT (nucleotides 627–647), which yield a 620 bp product. A LightCycler DNA Master SYBR Green I kit (Roche Molecular Biochemicals, Meylar, France) was used to perform GSTp RT–PCR on the LightCycler apparatus. The kit contains MgCl₂ 25 mM, LightCycler DNA Master SYBR Green I 10 × including deoxynucleotide triphosphate mix, MgCl₂ 10 mM, SYBR Green I dye and Hot Start Taq DNA polymerase. cDNA (2 μl), previously obtained, was amplified in duplicate (one incubation for GSTp, one incubation for GAPDH, the control gene) in a 20 μl reaction containing 2 μl of LightCycler DNA Master SYBR Green I 10 × , 1.6 μl of 25 mM MgCl₂ and 4 μl of one pair of primers 2.5 μM. In each experiment, a cDNA preparation of the RNA extracted from another CAL33 culture was introduced as the calibrator. Simultaneously, a blank was prepared as the negative control by incubating H₂O PCR grade instead of cDNA. The PCR protocol programmed on the LightCycler software consisted of three steps. The first step was denaturation of cDNA and activation of the enzyme for 8 min at 95°C. In the second step, DNA was amplified for 45 cycles of 15 s at 95°C, 13 s at 61°C and 26 s at 72°C. In the third step, the temperature was raised gradually (0.1°C s⁻¹) from the annealing temperature to 95°C to obtain melting curves and fusion temperatures of the amplicons synthesised. Results, calculated using RelQuant software, were expressed as the ratio of concentration of GSTp to GAPDH for a given sample, normalised by the same ratio for the calibrator.

Statistical analysis

Differences between the mean values were evaluated using either one-way ANOVA with Tukey’s test or one-way ANOVA on ranks with Dunnett’s or Student – Newman – Keuls test, according to data distribution. P = 0.05 was regarded as statistically significant. All analyses used SPSS software (Paris, France).

RESULTS AND DISCUSSION

Effects on cell proliferation (Figures 2, 3 and 9)

In the absence of drugs, CAL33 cell numbers increased approximately five-fold over 96 h. Figure 2A shows that ZD1839 markedly inhibited cell proliferation in a time-dependent manner. At the end of the longest drug exposure tested (96 h), ZD1839 reduced the final cell number by 60%; cisplatin – 5FU had a similar effect. The combination of ZD1839 and cisplatin – 5FU reduced the final cell number by 60%; cisplatin – 5FU had a similar effect. The combination of ZD1839 and cisplatin – 5FU reduced the final cell number by 60%; cisplatin – 5FU had a similar effect.
number at 96 h six-fold compared with untreated cells. This degree of decrease in cell numbers suggests at least additivity. Previously, we have reported synergy when combining ZD1839 and cisplatin–5FU under identical experimental conditions (Magne et al., 2002a).

Flow cytometry analysis showed that the application of ZD1839 led to an accumulation in the percentage of cells in the G0/G1 phase compared with control (25% higher, maximal effect at 24 h, Figure 2B) and this result was not dependent upon exposure time. Fewer cells exposed to ZD1839 were in the S phase, regardless of the duration of exposure. The cell cycle effects of ZD1839 and the cisplatin–5FU combination were quite different: the latter treatment generated a greater proportion of cells gathered in the S phase. It is interesting to note that the final cell cycle effects when ZD1839 was combined with cisplatin–5FU were very similar to those observed after ZD1839 alone. The fact that ZD1839 enhances the proportion of cells in the G1 phase may favour the effect of 5FU through incorporation into RNA, as previously pointed out by Maybaum et al. (1980).

Cyclin-dependent kinase (CDK) inhibitors are proteins that regulate the activities of CDK/cyclin complexes during the cell cycle. Many of the identified inhibitors, such as p21WAF1 and p27Kip1, act on G1-dependent kinases. ZD1839 exposure led, in CAL33 cells, to early increased expression of p21WAF1 and p27Kip1 with a maximum increase of 1.5- and two-fold, respectively, after 24 h (Figure 2C and D). These effects of ZD1839 on p21WAF1 and p27Kip1 agree well with those observed on the cell cycle. The present data obtained with ZD1839 are in line with previous data on tumour cells of head and neck origin concerning the upregulation of p27Kip1 caused by EGFR targeting with a specific monoclonal antibody (Huang et al., 1999). The cisplatin–5FU combination did not modify the cellular levels of these CDK inhibitors and no modulatory effect was observed in association with ZD1839.

We next examined the effects of ZD1839 on the final steps of EGFR signalling, p42/p44 (activated MAP kinase) and AKT (PI3 kinase pathway). Treatment of CAL33 cells with ZD1839 significantly reduced the level of phosphorylation of both MAP kinase and AKT (Figure 3A and B). Importantly, ZD1839 reduced p42/p44 levels by 25% at 72 and 96 h, and it is interesting to note that these inhibitory effects were more marked (approximately a reduction of two-fold) and occurred earlier on AKT phosphorylation than on...
p42/p44. The impact of cisplatin–5FU on p42/p44 was comparable to that observed in cells treated with ZD1839 alone. In contrast, treatment with cisplatin–5FU did not induce marked changes in AKT phosphorylation. For both p-MAP kinase and p-AKT, the combination of cisplatin–5FU with ZD1839 did not generally lead to greater effects than cisplatin–5FU alone or ZD1839 alone. These observations support the recent data reported by other investigators showing that EGFR antagonists deplete the activation of both PI3 kinase and MAP kinase in human head and neck cancer cell lines (Bancroft et al, 2002) and human breast cancer cell lines (Normanno et al, 2002).

Effects on apoptosis (Figures 4–7 and 9)

As concerns the exploration of parameters linked to apoptosis, there are two different well-identified pathways. First, the mitochondrial route, which reacts to various stimuli of cell aggression (internal or external). This apoptotic pathway is initiated by a change in mitochondrial permeability, which is regulated by Bcl2-related proteins, and more particularly by the Bax/Bcl2 ratio, which is under the control of p53; the mitochondrial efflux in cytochrome C leads to the immediate activation of caspase 9 followed by the activation of the effector caspase 3. This later caspase catalyses the degradation of various proteins linked to vital cellular processes. Since a Bax/Bcl2-mediated pathway has been implicated in the response to effective drug treatments, we examined the changes in these pro- and antiapoptotic proteins in the presence of each agent. As shown in Figure 4A and B, ZD1839 alone caused a downregulation of Bcl2 and an upregulation of Bax; both changes were already evident 24 h after treatment. Cisplatin–5FU had similar effects. As a corollary, ZD1839 alone caused an early and marked increase in the Bax/Bcl2 ratio maintained during all drug exposure and without modulatory effect caused by cisplatin–5FU (Figure 4C). This biochemical event likely reflects the capacity of EGFR targeting to upregulate the intrinsic apoptotic capacity of treated cells, as has been demonstrated by others (Giardello et al, 2002).

It is well established that, at an early stage, apoptotic stimuli alter ΔΨm. We used the amphiphilic cationic fluorochrome DiOC6(3) to monitor the changes in ΔΨm induced by ZD1839. Results are shown in Figure 5. Cells treated for different lengths of time exhibited differences in fluorescence intensity. After 48 h of ZD1839 exposure, the maximum decrease in cellular uptake of the fluorochrome measured with the DiOC6 probe reflects the collapse of ΔΨm, which is a signature for the opening of the mitochondrial megachannels, also called the permeability transition pores, in favour of involvement of the mitochondrial apoptotic pathway. In contrast, we observed an increase in DiOC6(3) fluorescence after 72 and 96 h of drug exposure, whatever the applied drug, although the Bax/Bcl2 ratio remained high.

Apart from the mitochondrial route, the cell death signal can be mediated through a receptor–ligand interaction via a membrane-linked death receptor family represented by tumour necrosis factor (TNF) and Fas. Fas (APO-1/CD95) is a member of the TNF receptor superfamily and can induce apoptosis when activated by its ligand FasL or by agonistic antibodies. The signalling cascade is initiated through the formation of a membrane death-inducing signalling complex that involves the recruitment of Fas-associated death domain protein and caspase 8. Neighbouring caspase 8 molecules within this newly formed multiprotein complex allow proteolytic autoactivation and the subsequent cleavage of downstream effector caspases (caspases 3, 6 and 7), leading to cell death. The impact of ZD1839 with or without cisplatin–5FU on Fas receptor expression and on caspase 8 activity was examined. Neither ZD1839 nor cisplatin–5FU had an impact on Fas receptor expression whatever the time of exposure (data not shown). This result is surprising because it has recently been shown that 5FU induces apoptosis, possibly via the Fas pathway (Backus et al, 2001). It seems, however, that Fas-mediated apoptosis stimulated by 5FU is dependent upon wild-type p53 status (Petak et al, 2000), a condition that is not fulfilled by the CAL33 cell line used in the present study. The lack of impact of ZD1839 on the death receptor pathway was confirmed by the absence of caspase 8 activity, whatever the applied drug and time of exposure (data not shown).

Results concerning caspase 3 were more informative. Interestingly, ZD1839 alone had no effect on caspase 3 activity, but the addition of ZD1839 to cisplatin–5FU led to a marked increase in...
caspase 3 activity at 96 h (Figure 6). Recently, caspase 3 activation has been shown to play an important role in cisplatin-induced apoptosis and to precede the morphological changes typical to apoptosis (Kolfschoten et al., 2002). We feel the supra-additive increase in caspase 3 activity in the presence of ZD1839 and cisplatin – 5FU is a molecular illustration of the synergistic interaction observed with this drug combination (Magne et al., 2002a). It is also interesting that ZD1839 alone had a minor effect on caspase 3 activity (only visible at 96 h) despite the fact that this drug was able to markedly upregulate the Bax/Bcl2 ratio. This later observation may be considered as a biochemical explanation of the radio- and chemo-sensitisation provided by EGFR-targeting drugs like ZD1839, which would be sustained by an underlying mechanism of enhancement of the intrinsic cellular apoptotic capacity.

It was striking to note that ZD1839 alone was able to markedly diminish p53 expression at 24–72 h with a maximum 2.5-fold decrease at 48 h; the inhibitory effect was smaller at 96 h (Figure 7). Moreover, cisplatin – 5FU alone or in association with ZD1839 had strictly no effect on p53 expression compared with controls at 72–96 h. Since changes in Bcl2 and Bax are in a great part under the control of p53 (Johnstone et al., 2002), one would expect the increase in Bax and the concomitant decrease in Bcl2 under ZD1839 to be accompanied by an upregulation of p53 levels in the presence of ZD1839. The same deduction holds true for the changes in p21 and those expected for p53. We have no clear explanation for these apparent contradictions; the present cell line was p53 mutated; this fact must be taken into consideration and it is plausible that this p53 status may influence the regulation of this protein under ZD1839. Thus, the fact that EGFR targeting modifies p53 cellular status merits further investigation.

Effects on DNA repair and detoxification mechanisms (Figures 8 and 9)

DNA damage activates several protein kinases, of which the prototypes are ATM, mutated in the human autosomal recessive disorder ataxia telangiectasia, and DNA-PK. A target of ATM is the tumour suppressor p53, maintained at low levels through interaction with the MDM2 protein that signals p53 degradation.

![Figure 6](image_url)  
**Figure 6** Impact of drugs and drug combination on caspase 3 activity. ZD1839 alone had no effect on caspase 3 activity, but the combination of ZD1839 with cisplatin–5FU led to a supra-additive increase in caspase 3 activity at 96 h. *P < 0.05 vs CFPU combination, bars indicate standard deviation from the mean of three separate experiments.

![Figure 7](image_url)  
**Figure 7** Impact of drugs and drug combination on p53. *P < 0.05 vs control, bars indicate standard deviation from the mean of three separate experiments.

![Figure 8](image_url)  
**Figure 8** Impact of drugs and drug combination on DNA-PK. *P < 0.05 vs control, bars indicate standard deviation from the mean of three separate experiments.

![Figure 9](image_url)  
**Figure 9** Representative Western blots related to Figures 2–4 and 8. For details on these analyses, see Materials and Methods section.
MDM2 is itself a target for DNA-PK. ZD1839 alone reduced DNA-PK expression by 25% compared with control. The application of cisplatin–5FU slightly increased DNA-PK expression (Figure 8). The combination of ZD1839 and cisplatin–5FU significantly reduced DNA-PK expression at 72 and 96 h. There was no impact on the DNA-repair protein ATM whatever the exposure time or the drug applied. The impact of ZD1839 on DNA-PK expression may be one explanatory phenomenon for the synergistic interaction between ZD1839 and cisplatin–5FU, because DNA repair is one of the biochemical modulators of cisplatin sensitivity (Perez, 1998). Furthermore, DNA-PK is involved in the repair of radiation-induced DNA damage, suggesting a role for ZD1839 in radio-sensitisation.

Glutathione, GSTπ and glutathione conjugate export pump have been shown to participate collectively in the detoxification of many anticancer drugs, including cisplatin (Perez, 1998). ZD1839 upregulated GSTπ expression after 24–72 h of exposure, with a maximum two-fold increase after 48 h. Similarly, cisplatin–5FU upregulated GSTπ at 96h. The combination of ZD1839 and cisplatin–5FU did not lead to additional effects on GSTπ. In contrast to the impact of ZD1839 on DNA-PK, this latter observation is not consistent with a synergistic interaction resulting from combining ZD1839 with cisplatin–5FU.

In summary, the present experimental study brings together numerous biochemical arguments that may sustain not only chemo-sensitisation but also radio-sensitisation (impact on DNA-PK) conferred by EGFR targeting. ZD1839 was thus able to impact on key cellular pathways controlling cell proliferation, apoptosis and DNA repair. Although the observations were obtained on a single human cancer cell line, the present data can serve as a rational basis to support clinical trials combining ZD1839 and cisplatin–5FU and also other protocols that combine EGFR targeting with chemotherapeutic drugs or radiotherapy.

REFERENCES

Backus HH, Dukers DF, van Groeningen CJ, Vos W, Bloemena E, Wouters D, van Riel JM, Smid K, Giaccone G, Pinedo HM, Peters GJ (2001) 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastasis of colorectal cancer patients. Ann Oncol 12: 209 – 216

Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, Jackson C, Van Waes C (2002) Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3 K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99: 538 – 548

Baselga J (2001) The EGFR as a target for anticancer therapy – focus on cetuximab. Eur J Cancer 37 (Suppl 4): S16 – S22

Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller Jr WH, Mendelsohn J (1993) Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85: 1327 – 1333

Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, Mendelsohn J, De Placido S, Bianco AR, Ciardiello F (2000) Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligodeoxynucleotide. Clin Cancer Res 6: 4343 – 4350

Bonner JA, Raisch KP, Trumnell HH, Roberts F, Meredith RF, Spencer SA, Buchsbaum DJ, Saleh MN, Stackhouse MA, LoBuglio AF, Peters GE, Carroll WR, Wakasal HW (2000) Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 18 (21 Suppl): 475 – 535

Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbuzzrese JL, Hicklin DJ, Radinsky R (2000) Epidermal growth factor receptor blockade with C225 plus gemcetabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6: 1936 – 1948

Cabelguenne A, Lorio MA, Stucker I, Blons H, Koun-Besson E, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P, De Waziers I (2001) Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. Int J Cancer 93: 725 – 730

Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate – phenol – chloroform extraction. Anal Biochem 162: 156 – 159

Chou T, Talalay P (1984) Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27 – 55

Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G (1999) Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5: 909 – 916

Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G (2002) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 8: 2053 – 2063

Ciardiello F, Caputo R, Borrelli G, Del Bufalo D, Biroccio A, Zupi G, Bianco AR, Tortora G (2002) ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 98: 463 – 469

Fan Z, Baselga J, Masui H, Mendelsohn J (1993) Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diaminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53: 4637 – 4642

Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste JF, Kudo S, Averbuch S, Macleod A, Feyereslova A, Baselga J (2002) Final results from a phase II trial of ZD1839 (‘Iressa’) for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 21: 298a (abstract 1186)

Huang SM, Bock J, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59: 1935 – 1940

Huang SM, Harari PM (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6: 2166 – 2174

Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP (2000) Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 6: 4874 – 4884

Johnstone RW, Rueff AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 133 – 164

Kolfschoten GM, Hulscher TM, Schier SM, van Houten VM, Pinedo HM, Boven E (2002) Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin. Gynecol Oncol 84: 404 – 412

Magne N, Fischl JL, Dubreuil A, Formento P, Marcic S, Lagrange JL, Milano G (2002a) Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 86: 819 – 827

Magne N, Fischl JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, Milano G (2002b) Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’). Br J Cancer 86: 1518 – 1523

Maybza J, Ullman B, Mandel HG, Day JL, Sadee W (1980) Regulation of RNA- and DNA-directed actions of 5-fluorourimidines in mouse T-lymphoma (S-49) cells. Cancer Res 40: 4209 – 4215

Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z (2000) In vivo enhancement of tumor radioresponse by C225 antipidermidermal growth factor receptor antibody. Clin Cancer Res 6: 701 – 708

Natale RB, Saleh M, Stella PJ, Heyes A, Helms L, Ochs J, Averbuch S, Wolf M, Kay A
Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Proc Am Soc Clin Oncol 21: 292a (abstract 1167)
Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S (2002) Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13: 65–72
Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ (2000) Epidermal growth factor receptor blockade by antibody IMC-225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89: 74–82
Perez RP (1998) Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535–1542
Petak I, Tillman DM, Houghton JA (2000) p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil–leucovorin in human colon carcinoma cell lines. Clin Cancer Res 6: 4432–4441
Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS, Kim HG, Meredith RF, Wheeler RH, Buchsbaum DJ (1999) Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 14: 451–463
Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885–4892
Williams KJ, Telfer BA, Stratford IJ, Wedge SR (2002) ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86: 1157–1161
Yarden Y (2001) The EGFR family and its ligands in human cancer; signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 (Suppl 4): S3–S8

(2002) Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Proc Am Soc Clin Oncol 21: 292a (abstract 1167)